Unfortunately, no one here can answer this for you. This Q is better directed towards the company via email.
At this early stage though, I would recommend awaiting further anns about large tenders/contracts and maybe significant FY22 rev changes, before wondering about AT1's 10m prof test supply running out.
AT1 likely won't move even 50% prof kit stock in Jan-Mar'22 months alone (without landing some massive gov tenders and/or commercial contracts - order sizes for m's of kits - which would have to be ann'd)
eg: even if there is a v high runrate of commercial sales for a variety of customers (eg: 500k+ per month), AT1 will have shifted only 6m+ prof kits by Dec'22.
Ditto for the 10m self-test option (available for NZ sales for now). Post the AU TGA approval, it will then start another 3-6-9mth cycle of new consumer supply sale contracts, ordering, fulfiment etc to shift any significant portion of the additional 10m self-test stock. Its going to take many CY22 mths (and maybe CY23 also) of v solid consumer sales to run out of this option too.
The 1HFY22 report will be out by 31 Mar - which does seem far away but in reality between fulfilling pending Q2 orders, signing new Q3 contracts (Au+NZ), time for AccBio to provide more stock, air shipment availability from USA, shipping time locally to actual payment & rev recognition, it will likely be 2nd half of CY22 when we can start wondering about getting more AccBio stock.
Certainly I hope AT1 has enough whale contracts in the pipeline already for prof + future self-test stock, which could easily see it moving all 20m in next 6mths....but against many Dx companies bringing in everything they can access also, I think its going to be competitively hard to move m's of kits easily.
- Forums
- ASX - By Stock
- AT1
- Media Update
Media Update, page-1661
-
-
- There are more pages in this discussion • 185 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
KAI
Pilbara Minerals buys land off Kairos part of its York gold project for $20M – and a 2% royalty on any PLS gold sales
AVH
Avita boosts skin restoration product portfolio with 'dermal matrix' – a kind of next-level gauze made of fake skin
Add AT1 (ASX) to my watchlist
(20min delay)
|
|||||
Last
2.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.34M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 497908 | 2.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.5¢ | 67200 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 497908 | 0.023 |
6 | 725023 | 0.022 |
4 | 217292 | 0.021 |
2 | 250000 | 0.020 |
1 | 26316 | 0.019 |
Price($) | Vol. | No. |
---|---|---|
0.025 | 67200 | 3 |
0.026 | 390045 | 2 |
0.027 | 648550 | 3 |
0.028 | 155890 | 3 |
0.029 | 425248 | 5 |
Last trade - 16.12pm 02/08/2024 (20 minute delay) ? |
Featured News
MND
Albemarle lithium downsize burns $200M hole in Monadelphous's pocket as latter's contracts terminated
GML
Gateway Mining sells WA Eastern Montague gold project to Brightstar for $14M – half of that in shares
AT1 (ASX) Chart |
Day chart unavailable